Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant add-on therapy in uncontrolled severe eosinophilic asthma
2015-002553-35Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fevipiprant in asthma (3 arms), sponsored by Novartis. Primary endpoint: Rate of moderate-to-severe asthma exacerbations. Started Sep 2015; status: completed.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on 2015-002553-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002553-35.